GlobalData
GlobalData

Press Release

Family travel to increase by 25% by 2022, says GlobalData

The outbound family travel market will grow at a Compound Annual Growth Rate (CAGR) of 4.6% from 300 million trips in 2017 to 376 million in 2022*, according to , a leading data and analytics company. The company’s latest report, highlights that family travel accounts for 30.8% of outbound tourism and will retain its hold […]
Read more

Dunkin’ Donuts’ coffee rebrand to target 42% of consumers that visited a coffee or tea shop in the past week, says GlobalData

In its 2017 annual report, Dunkin’ revealed its most valuable products according to consumer demand, were hot coffees, out-of-home drinks and iced coffees, instead of their core baked goods range, observes , a leading data and analytics company. In line with this, st report, reveals that consumers’ preference for Coffee & Tea shops has not […]
Read more

Novo Nordisk’s NN9924 has potential to become new market leader in GLP-1RA space within the next decade, says GlobalData

Novo Nordisk’s NN9924 is on track to become the first-to-market oral GLP-1RA within the next decade, says GlobalData, a leading data and analytics company. The growth in the GLP-1RA space will be heavily driven by agents that confer glycemic benefit, weight loss, and cardiovascular (CV) benefit, and increased patient compliance. In anticipation of GLP-1RA market […]
Read more

Copiktra Wins FDA Approval in FL, CLL, and SLL, but its commercial prospects are limited, says GlobalData

Following Verastem’s Copiktra (duvelisib) accelerated approval for the treatment of third-line follicular lymphoma (FL) in September 2018, as well as its standard approval for third-line chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): Arshad Ahad, Oncology and Hematology Analyst GlobalData, offers his view on its commercial prospects: “Copiktra may have trouble gaining commercial traction […]
Read more

Knowledge about current contraceptive options is still a problem in highly developed countries, says GlobalData

Women in the US are still not fully aware about the available choices of contraceptives and receive outdated or incorrect counselling as their general providers are not familiar with currently available options, particularly the long-acting reversible methods, according to GlobalData, a leading data and analytics company. September 26 marks World Contraception Day (WCD), which aims […]
Read more

Limited access to novel therapies could hinder effective personalized cancer treatment in the UK, says GlobalData

NICE recently rejected NHS funding of Kymriah for DLBCL despite recognizing that the drug has significant clinical benefits. As a result, patients with DLBCL in the UK could now potentially lose out on receiving life-saving treatment, according to GlobalData, a leading data and analytics company. Following the EMA approval of Novartis’ Kymriah (tisagenlecleucel) for refractory/relapsed […]
Read more

Coca-Cola’s acquisition of Costa Coffee is set to take over supermarket shelves, says GlobalData

Coca-Cola’s acquisition of Costa Coffee offers the opportunity to turbo-charge the brand’s retail operations, and become a mainstay of supermarket shelves worldwide, says GlobalData, a leading data and analytics company. Ronan Stafford, Lead Consumer Analyst at GlobalData, comments, “With Costa Coffee operating in many of the world’s largest retail markets for hot coffee, Coca-Cola will […]
Read more

NHS victory over Bayer and Novartis could have significant impact on UK ophthalmology sales, says GlobalData

Following a High Court case won by twelve NHS Clinical Commissioning Groups (CCGs) in favor of prescribing the significantly cheaper anti-vascular endothelial growth factor (anti-VEGF), Avastin (bevacizumab), over Novartis’ and Bayer’s licensed anti-VEGF eye drugs, Edit Kovalcsik, Managing Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the likely outcome […]
Read more
1 43 44 45 46 47 61